AvoMed
Biowaste-based Bioactive Compound for Dermal Disorders
Company Overview
Snapshot
Founded in June 2016, AvoMed operates with 1–10 employees. The company secured its seed funding in August 2022, with PipelBiz participating as an investor. AvoMed focuses on developing bioactive compounds from biowaste for dermal applications.
Business overview
AvoMed specializes in the development and manufacturing of AvoMed PFA, a patented bioactive compound derived from avocado pits. This compound is designed as an active ingredient for personal care products and for treating dermal disorders such as psoriasis and atopic dermatitis. The company's technology, backed by over six years of research and preclinical/clinical studies, targets damage caused by UV radiation, pollution, aging, and other stressors, also demonstrating effectiveness in inhibiting phospholipase A2 and other dermal inflammatory conditions. AvoMed operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving healthcare providers, biotechnology firms, and cosmetic companies.
Strategic signal
In August 2022, AvoMed's research on using avocado seeds to heal skin conditions gained significant media attention, highlighting the potential of their biowaste-based bioactive compound. This widespread coverage validates the company's innovative approach to leveraging natural ingredients for dermatological solutions and signals a strong market interest in sustainable and effective treatments for skin disorders.
Company Intelligence Q&A
- What is AvoMed's primary product?
- AvoMed's primary product is AvoMed PFA, a patented bioactive compound extracted from avocado pits, designed to enhance personal care products and treat dermal disorders.
- When was AvoMed founded?
- AvoMed was founded in June 2016.
- What is the status of AvoMed's operations?
- AvoMed is currently non-active, having ceased operations in December 2022.
- Which investor participated in AvoMed's seed funding round?
- In August 2022, PipelBiz participated as an investor in AvoMed's seed funding round.
- What types of dermal disorders does AvoMed's compound aim to treat?
- AvoMed's compound aims to treat dermal disorders such as psoriasis and atopic dermatitis, and addresses damage caused by UV radiation, pollution, aging, and other stressors.